BRACAnalysis® is a genetic test that detects the presence of a BRCA1 or BRCA2 gene mutation. The results of the BRACAnalysis test enable the development of patient-specific medical management plans to significantly reduce the risk of cancer. Additionally, this information can help inform treatment decisions related to PARP inhibitor therapy.1-4
Inform Treatment Decisions
- Cancer cells with BRCA1 or BRCA2 mutations are more susceptible to PARP inhibitors and treatments that directly or indirectly damage DNA (DNA damaging agents).1-4
- Knowing BRCA1 and BRCA2 status may inform treatment decisions related to PARP inhibitors and DNA damaging agents
How does testing impact treatment decisions related to PARP inhibitors and DNA damaging agents?
Manage Future Cancer Risk
- If BRACAnalysis® testing identifies the presence of a BRCA1 or BRCA2 mutation, medical management options may help reduce cancer risk and may either delay the onset of cancer, detect cancer at an earlier, more treatable stage or even prevent it.
- First-degree relatives of these patients are at a 50% risk for carrying the mutation.
- Those relatives who are positive may benefit from increased surveillance and/or preventive measures.
In the SOLO2 trial, a significant improvement in progression-free survival in patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer when treated with the PARP inhibitor olaparib. Other studies such as Study 19, ARIEL2 and NOVA demonstrated that a germline BRCA1/2 mutation can be a predictor of increased efficacy with PARP inhibitor therapy.
Explore our publications to learn more about how BRCA1/2 testing can impact treatment decisions related to PARP inhibitor therapy and DNA-damaging chemotherapy in ovarian cancer.
* BRACAnalysis CDx has been approved by the FDA for patients with breast and ovarian cancer who are or may become eligible for treatment with the PARP inhibitor Lynparza® (olaparib). BRACAnalysis CDx can also identify patients with ovarian cancer who may experience enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. myRisk, myChoice HRD and BRACAnalysis have not been reviewed or approved by the FDA.1,2
- Robson et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med (2017). 377:523-533
- Kristeleit et al. Presented at European Cancer Congress 2016 (Abstract 8560).
- Lheureux et al. J Clin Oncol (2015). 33 (suppl;abstr 5566).
- Pujade-Lauraine et al. Lancet Oncol (2017). ttp://dx.doi.org/10.1016/S1470-2045(17)30469-2